Do You want daily job updates ?
Click here and enter your mail id.
Monday, 24 October 2016
Friday, 21 October 2016
Pioneer a brighter future
At Novozymes, we work in close partnership with our customers to make an impact and help create a better world. For those around us, for each other and for the next generation. We use science to advance industries, and as part of R&D, you will create and develop the biological answers that will pave the way for a brighter future.
Job Title : Research Associate, Regional Innovation, R&T, Bengaluru
Are you ready for a challenging role that lets you use both your scientific grounding and communication skills? If so, you could be our new colleague in Regional Innovation India. You’ll be part of a dynamic team of 10 scientists, research associates and technicians based in Bengaluru and will assist in developing new applications in the lab and transfer the technology to plant scale. You thrive in afast-paced environment and are as comfortable with taking end-to-end ownership of laboratory tasks assigned to you and deliver on-time results with high-quality of documentation as you are with working in plants for trials, as required. For the right individual, this is a fantastic career opportunity with potential for personal and professional development.
Apply here
At Novozymes, we work in close partnership with our customers to make an impact and help create a better world. For those around us, for each other and for the next generation. We use science to advance industries, and as part of R&D, you will create and develop the biological answers that will pave the way for a brighter future.
Job Title : Research Associate, Regional Innovation, R&T, Bengaluru
Are you ready for a challenging role that lets you use both your scientific grounding and communication skills? If so, you could be our new colleague in Regional Innovation India. You’ll be part of a dynamic team of 10 scientists, research associates and technicians based in Bengaluru and will assist in developing new applications in the lab and transfer the technology to plant scale. You thrive in afast-paced environment and are as comfortable with taking end-to-end ownership of laboratory tasks assigned to you and deliver on-time results with high-quality of documentation as you are with working in plants for trials, as required. For the right individual, this is a fantastic career opportunity with potential for personal and professional development.
Apply here
Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. With successful initiatives in drug discovery and development, bioprocessing, manufacturing and global marketing, Biocon delivers products and solutions to partners and customers in over 75 countries. Biocon has the defining science, world class capabilities and a focused vision to deliver the promise of innovative and affordable medicine to a waiting world. Today, Biocon together with group companies employs more than 5000 employees with approximately Rs 2500 crore turnover and is expected to grow further during the current financial year .
Job Title : Scientist Analytical R&D
Job Location : Bengaluru/Bangalore
Apply here
Job Title : Scientist Analytical R&D
Job Location : Bengaluru/Bangalore
Apply here
Sun Pharma an international,specialty pharmaceutical company headquartered in India with a global manufacturing network across 25 countries. We manufacture and market a large basket of pharmaceutical formulations as branded generics & generics in India, US and across the world. Our leadership is approachable, encourages transparency & strong work ethics to ensure that people get the best opportunities to learn and grow. We encourage our employees to challenge themselves for highest level of performance through greater bandwidth of work responsibilities and growth opportunities. Apply to us if you wish to be part of Sun Pharma growth story
Post : OFFICER / SR. OFFICER / EXECUTIVE
Interested candidates may Walk-in for an Interview along with current salary supportings (Annual ctc structure) & photograph between 9.30 am to 5.00 pm on 23rd OCTOBER 2016 (Sunday) at HOTEL PICCADILY, Himalaya Marg. Sector 22 - B. CHANDIGARH -160022.
Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.We offer stimulating work environment & a career that spells growth. In tune with our plans, we require young, aggressive, dynamic, high performing and result oriented professional.
Post: Business Development Executives (MRs)
Eligible candidates can appear for Walk-in-Interviews between 0900-1700Hrs and/or send their applications at careersales@panaceabiotec.com
Job Description:
- Process adverse event reports received from sites/reporters.
- Perform QC review of completed individual and periodic safety reports.
- Complete data entry including writing of adverse event narrative and provide preliminary assessment of event seriousness and expectedness/listedness as per applicable Reference Safety Information.
- Generate adverse event queries, liaise with the medical reviewers/client to agree upon the queries, and send request for additional information to the sites/reporter.
- Engage with the Site Monitors to ensure follow up information is obtained from site effectively.
- Foster constructive and professional working relationships with all project team members, internal and external.
- File documents according to project specific requirements (electronically or in hard copy as applicable).
- Ensure case files are compliant with SOPs.
Apply now
- Process adverse event reports received from sites/reporters.
- Perform QC review of completed individual and periodic safety reports.
- Complete data entry including writing of adverse event narrative and provide preliminary assessment of event seriousness and expectedness/listedness as per applicable Reference Safety Information.
- Generate adverse event queries, liaise with the medical reviewers/client to agree upon the queries, and send request for additional information to the sites/reporter.
- Engage with the Site Monitors to ensure follow up information is obtained from site effectively.
- Foster constructive and professional working relationships with all project team members, internal and external.
- File documents according to project specific requirements (electronically or in hard copy as applicable).
- Ensure case files are compliant with SOPs.
Apply now
Job Description
1.Write/edit regulatory documents (e.g. CSRs, DSURs, RMPs, contribute to CTD summaries).
2.Participate in planning of analysis and data presentation to be used in study reports or summary documents.
3.Act as a member of clinical trial teams following protocol finalization
4.Act as documentation consultant in clinical trial teams to ensure compliance of documentation to internal company standards and external regulatory guidelines.
5.Act as project medical writer for various programs in clinical development and ensure medical writing resource allocation to studies within these programs.
6.Contribute to process improvement initiatives
7.Supervise outsourcing to external medical writers.
8.Follow and track clinical trial milestones and resource requirements for assigned projects
9.Training and mentoring of associates as required.
Apply now
1.Write/edit regulatory documents (e.g. CSRs, DSURs, RMPs, contribute to CTD summaries).
2.Participate in planning of analysis and data presentation to be used in study reports or summary documents.
3.Act as a member of clinical trial teams following protocol finalization
4.Act as documentation consultant in clinical trial teams to ensure compliance of documentation to internal company standards and external regulatory guidelines.
5.Act as project medical writer for various programs in clinical development and ensure medical writing resource allocation to studies within these programs.
6.Contribute to process improvement initiatives
7.Supervise outsourcing to external medical writers.
8.Follow and track clinical trial milestones and resource requirements for assigned projects
9.Training and mentoring of associates as required.
Apply now
Job Description:
- Design & implement work flow processes.
- Ensure quality of Deliverables
- Interaction with clients and ensure timely communication
- Ensure proper execution of projects
- Monitor the quality of the team
- Accountable for Team performance and Quality
- Conduct and recommend trainings to improve team performance
- Manage Customer Engagement and Client Interaction when needed
- Maintain process documents and ensure regular updates
- Ensure all updates from clients are recorded
- Ensure proper allocation of work to team members
- Participate in conference calls with the clients/ top management
- Apply here
Sun Pharma on Friday said it has completed buyback of shares worth Rs 675 crore to return surplus funds to its shareholders.
"The company on October 18 completed buyback of 75 lakhs fully paid-up shares of the face value of Rs 1 each (representing about 0.31 per cent of the total outstanding pre-buyback shares of the company) at a price of Rs 900 per share for an aggregate amount of Rs 675 crore," Sun Pharma said in a BSE filing.
In June this year, the company had announced its decision to buy back shares.
"The buyback is being undertaken by the company to return surplus funds to the equity shareholders, enhancing the overall returns to the shareholders," the company had earlier said.
source:http://www.business-standard.com/article/companies/sun-pharma-completes-rs-675-crore-share-buyback-116102100231_1.html
If aliens were to examine a human, they would think we were just slavish organisms designed to feed microbes and carry them around. Our bodies contain ten times more bacteria than cells, and there are an estimated 3.3 million genes in the total bacteria DNA, which is 160 times the number of human genes. Our intestine hosts about one kilogram of bacteria which help to digest and metabolise food, produce vitamins and protect us from infections.
The above is textbook knowledge, but loads of recent studies are uncovering new and unsuspected roles for these little companions. There is evidence that gut bacteria can protect or predispose us to pathologies ranging from inflammation to diabetes and obesity. And, as far-fetching as it sounds, a remarkable amount data shows that they can even modify our mood and behaviour.
Microbes are hot on the scientific agenda. In May, the US government launched a National Microbiome Initiative with an overall budget of half a billion dollars, while the EU is funding more than 300 projects related to the microbiome.
Yolanda Sanz, a researcher at the Institute of Agrochemistry and Food Technology (IATA) of the Spanish National Research Council in Valencia, Spain, coordinates MyNewGut, the largest EU consortium in the field with 30 partners in 15 Countries. We asked Sanz about the perspectives of research and the intriguing connections between the microbiome and the brain.
source:https://www.sciencedaily.com/releases/2016/10/161020114611.htm
Microbes are hot on the scientific agenda. In May, the US government launched a National Microbiome Initiative with an overall budget of half a billion dollars, while the EU is funding more than 300 projects related to the microbiome.
Yolanda Sanz, a researcher at the Institute of Agrochemistry and Food Technology (IATA) of the Spanish National Research Council in Valencia, Spain, coordinates MyNewGut, the largest EU consortium in the field with 30 partners in 15 Countries. We asked Sanz about the perspectives of research and the intriguing connections between the microbiome and the brain.
source:https://www.sciencedaily.com/releases/2016/10/161020114611.htm
Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. With successful initiatives in drug discovery and development, bioprocessing, manufacturing and global marketing, Biocon delivers products and solutions to partners and customers in over 75 countries. Biocon has the defining science, world class capabilities and a focused vision to deliver the promise of innovative and affordable medicine to a waiting world. Today, Biocon together with group companies employs more than 5000 employees with approxmimately Rs 2500 crore turnover and is expected to grow further during the current financial year .
Walk-in at Aurangabad for Insulin Manufacturing
Apply now
Walk-in at Aurangabad for Insulin Manufacturing
Apply now
Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. With successful initiatives in drug discovery and development, bioprocessing, manufacturing and global marketing, Biocon delivers products and solutions to partners and customers in over 75 countries. Biocon has the defining science, world class capabilities and a focused vision to deliver the promise of innovative and affordable medicine to a waiting world.
Job Title – Executive
Location – Bangalore/Bengaluru
Experience – 0 – 2 Years
Apply here
Job Title – Executive
Location – Bangalore/Bengaluru
Experience – 0 – 2 Years
Apply here
Johnson & Johnson is the world’s most comprehensive and broadly based manufacturer of health care products. The organization is comprised of more than 250 operating companies with over 128,000 employees located in some 60 countries. With Global sales of USD 67.2 billion in 2012, Johnson & Johnson is recognized as one of the most admired and respected companies in the world. In India, Johnson & Johnson operates as a single legal entity and consists of the 3 strategic business units: Consumer Products, Pharmaceuticals and Medical Devices & Diagnostics, which are independently managed and report into their respective Global business segments.
Job Title: Quality Control Officer – Microbiology (Regional Title: Q&C Engineer)
Function: Quality & Compliance
Organization: Johnson & Johnson Limited, Consumer, INDIA
Location: Johnson & Johnson Ltd., Hyderabad, INDIA
Apply now
Job Title: Quality Control Officer – Microbiology (Regional Title: Q&C Engineer)
Function: Quality & Compliance
Organization: Johnson & Johnson Limited, Consumer, INDIA
Location: Johnson & Johnson Ltd., Hyderabad, INDIA
Apply now
Applications are invited for one position each of Laboratory Technician and Data Entry Operator under AIIMS and NIPER Collaborative project titled “New Biotherapeutic Approaches to the Treatment of Tuberculosis” funded by DoP, MC&F, New Delhi.
Post Name : Laboratory Technician
Educational Qualification : Aggregate 55% marks in M. Sc. biochemistry, biotechnology, zoology, microbiology, life sciences, M. (Pharm) in Biotechnology or Pharmacology.
Upper age limit: 28 yrs. (relaxation: 05 yrs. for SC/ST/PH/OBC/woman candidates). Qualification/experience can be relaxed for deserving candidates with relevant experience in the project area.
Apply here
Post Name : Laboratory Technician
Educational Qualification : Aggregate 55% marks in M. Sc. biochemistry, biotechnology, zoology, microbiology, life sciences, M. (Pharm) in Biotechnology or Pharmacology.
Upper age limit: 28 yrs. (relaxation: 05 yrs. for SC/ST/PH/OBC/woman candidates). Qualification/experience can be relaxed for deserving candidates with relevant experience in the project area.
Apply here
Job Description:
- Design & implement work flow processes.
- Ensure quality of Deliverables
- Interaction with clients and ensure timely communication
- Ensure proper execution of projects
- Monitor the quality of the team
- Accountable for Team performance and Quality
- Conduct and recommend trainings to improve team performance
- Manage Customer Engagement and Client Interaction when needed
- Maintain process documents and ensure regular updates
- Ensure all updates from clients are recorded
- Ensure proper allocation of work to team members
- Participate in conference calls with the clients/ top management
Job Description
Coordinates the development and implementation of Standard Operating Procedures and Working Practice Documents. Interacts extensively with a multi-disciplinary senior management team to identify critical needs and develop strategic initiatives.
Coordinates process improvement and implements programming standards.
Provides programming oversight for strategic client relationships, and/or oversight for significant client portfolios.
Understands and follows department's working practice documents and SOPs, and contribute to their development as needed.
Understands and follows appropriate corporate SOPs.
Participates in client contract negotiations when modifications are required.
Participates in senior management meetings and be an active participant in long range department planning.
Interacts with business development and visits client sites in an effort to develop client relationships for current and future projects.
Increases knowledge base and professional skills of staff in areas including programming technology and techniques, clinical trials, and the pharmaceutical industry through on the job training, mentoring, and internal or external training courses.
Coordinates process improvement and implements programming standards.
Provides programming oversight for strategic client relationships, and/or oversight for significant client portfolios.
Understands and follows department's working practice documents and SOPs, and contribute to their development as needed.
Understands and follows appropriate corporate SOPs.
Participates in client contract negotiations when modifications are required.
Participates in senior management meetings and be an active participant in long range department planning.
Interacts with business development and visits client sites in an effort to develop client relationships for current and future projects.
Increases knowledge base and professional skills of staff in areas including programming technology and techniques, clinical trials, and the pharmaceutical industry through on the job training, mentoring, and internal or external training courses.
Job Description
Participate in the regulatory activities of full spectrum of formulation development, from clinical trials to marketing to post approval activities.
Ensure the appropriate licensing, marketing and legal compliance of the finished dosages.
Review the documents at each stage of formulations development.
Highlight the regulatory issues that can be there and try to resolve them.
Coordinate with R&D, AR&D, QA, etc. to collect the complete set of documents.
Compile the ANDA document to be submitted to FDA.
Ensure the documents are error free and have minimum deficiencies.
Prepare annual reports and send them to FDA.
Manage change controls and deviation controls.
Keep themselves abreast of international legislation, guidelines and customer practices
Develop and write clear arguments and explanations for new product licenses and license renewals.
Advise PDTs on regulatory requirements.
Respond to the queries of Regulatory authorities and customers on time.
Review the process change proposals and provide guidance on change proposals.
Ensure the appropriate licensing, marketing and legal compliance of the finished dosages.
Review the documents at each stage of formulations development.
Highlight the regulatory issues that can be there and try to resolve them.
Coordinate with R&D, AR&D, QA, etc. to collect the complete set of documents.
Compile the ANDA document to be submitted to FDA.
Ensure the documents are error free and have minimum deficiencies.
Prepare annual reports and send them to FDA.
Manage change controls and deviation controls.
Keep themselves abreast of international legislation, guidelines and customer practices
Develop and write clear arguments and explanations for new product licenses and license renewals.
Advise PDTs on regulatory requirements.
Respond to the queries of Regulatory authorities and customers on time.
Review the process change proposals and provide guidance on change proposals.
Consumers don’t always read the risk information on branded drug websites--even though they say they do, according to new eye-tracking research from the University of Tennessee. Risk disclosures are a hot-button issue in pharma marketing, with some critics accusing brands of downplaying the risks and marketers contending that they follow the rules laid out by the FDA.
For the eye-tracking study, two advertising professors used the technique on 29 seasonal allergy sufferers to determine where and how long they looked at a branded drug website, then followed up with interviews about how much the people read and what they remembered. The participants were told the study was looking at how people look for health information online and that the website was for a new prescription allergy drug.
The key finding? Even though 80% of the participants said they read half or more of the website information, they actually read much less than that and had limited recall of the drug’s risks. Further, the study found consumers focused on the drug’s benefit and generally ignored the risks.
That figure wouldn't necessarily hold true for other drugs, though. Mariea Hoy, who fielded the research along with former UT faculty member Abbey Levenshus, said perceived familiarity in the case of the seasonal allergy drug may have played a role in participants ignoring risks they thought they already knew about or didn’t believe would affect them.
“There are so many factors that may be influencing a person when looking at the drug website. Our study found that for individuals who perceived themselves to be familiar with the condition and the drugs that treated it, and subsequently thought ‘it's just an allergy drug,’ they were only looking for benefits and subsequently ignored the risk information,” Hoy said in an email interview with FiercePharma.
source:http://www.fiercepharma.com/marketing/eyes-don-t-lie-eye-tracking-study-finds-people-don-t-really-read-risks-drug-websites
For the eye-tracking study, two advertising professors used the technique on 29 seasonal allergy sufferers to determine where and how long they looked at a branded drug website, then followed up with interviews about how much the people read and what they remembered. The participants were told the study was looking at how people look for health information online and that the website was for a new prescription allergy drug.
The key finding? Even though 80% of the participants said they read half or more of the website information, they actually read much less than that and had limited recall of the drug’s risks. Further, the study found consumers focused on the drug’s benefit and generally ignored the risks.
That figure wouldn't necessarily hold true for other drugs, though. Mariea Hoy, who fielded the research along with former UT faculty member Abbey Levenshus, said perceived familiarity in the case of the seasonal allergy drug may have played a role in participants ignoring risks they thought they already knew about or didn’t believe would affect them.
“There are so many factors that may be influencing a person when looking at the drug website. Our study found that for individuals who perceived themselves to be familiar with the condition and the drugs that treated it, and subsequently thought ‘it's just an allergy drug,’ they were only looking for benefits and subsequently ignored the risk information,” Hoy said in an email interview with FiercePharma.
source:http://www.fiercepharma.com/marketing/eyes-don-t-lie-eye-tracking-study-finds-people-don-t-really-read-risks-drug-websites
Novartis will partner with Cerulean Pharma to develop nanoparticle-drug conjugates (NDCs) that combine Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds, to be directed at up to five undisclosed cancer targets.
Cerulean said today it will generate $5 million upfront through the companies’ collaboration, plus funding for five full-time equivalent employees. Cerulean may potentially make millions more in payments tied to achieving preclinical, clinical, regulatory, and sales milestones for each target. Following regulatory approvals, Cerulean could also earn single-digit to low double-digit tiered royalties on net sales for each NDC product.
Under the collaboration, Cerulean will create NDC candidates using its Dynamic Tumor Targeting platform, with Novartis agreeing to oversee further development and commercialization of those products.
“This collaboration is further validation of our powerful technology platform, and we are excited that Novartis is including NDCs in its drug discovery and development efforts,” Cerulean president and CEO Christopher D.T. Guiffre said in a statement.
Separately, Cerulean said that a longtime shareholder, the institutional investor Aspire Capital Fund, has agreed to purchase $20 million of the company’s common stock— 800,000 shares at $1.25 per share. Cerulean also has the right to sell up to the remaining $19 million of its common stock to Aspire over 24 months, at prices based on a formula linked to current market prices at the time of each sale.
“This agreement with Aspire provides us access to capital to support our ongoing clinical efforts,” Giuffre noted. “We can use this facility to opportunistically strengthen our balance sheet without unnecessary dilution as we advance our CRLX101 and CRLX301 programs.”
source:http://www.genengnews.com/gen-news-highlights/novartis-to-develop-cerulean-nanoparticle-drug-conjugates-in-cancer-collaboration/81253338
Cerulean said today it will generate $5 million upfront through the companies’ collaboration, plus funding for five full-time equivalent employees. Cerulean may potentially make millions more in payments tied to achieving preclinical, clinical, regulatory, and sales milestones for each target. Following regulatory approvals, Cerulean could also earn single-digit to low double-digit tiered royalties on net sales for each NDC product.
Under the collaboration, Cerulean will create NDC candidates using its Dynamic Tumor Targeting platform, with Novartis agreeing to oversee further development and commercialization of those products.
“This collaboration is further validation of our powerful technology platform, and we are excited that Novartis is including NDCs in its drug discovery and development efforts,” Cerulean president and CEO Christopher D.T. Guiffre said in a statement.
Separately, Cerulean said that a longtime shareholder, the institutional investor Aspire Capital Fund, has agreed to purchase $20 million of the company’s common stock— 800,000 shares at $1.25 per share. Cerulean also has the right to sell up to the remaining $19 million of its common stock to Aspire over 24 months, at prices based on a formula linked to current market prices at the time of each sale.
“This agreement with Aspire provides us access to capital to support our ongoing clinical efforts,” Giuffre noted. “We can use this facility to opportunistically strengthen our balance sheet without unnecessary dilution as we advance our CRLX101 and CRLX301 programs.”
source:http://www.genengnews.com/gen-news-highlights/novartis-to-develop-cerulean-nanoparticle-drug-conjugates-in-cancer-collaboration/81253338
Subscribe to:
Posts (Atom)
Posts
